eGenomics has developed a predictive epidemiological system that uses rapid DNA sequencing and analytical computer software to track and predict the spread of bacteria, viruses and fungi in hospitals and other high-risk environments.

The company was founded by Dr. Barry Kreiswirth and Steve Naidich as the result of their long-term collaboration studying DNA fingerprinting and nosocomial infections. Their research has been published recently in the prestigious journals "Proceedings of the National Academy or Sciences", "Nature Medicine", "The Journal of Infectious Diseases", and "The Journal of Clinical Microbiology", to name a few.

Dr. Kreiswirth is a renowned infectious disease expert having pioneered the techniques of molecular fingerprinting with his research studying M. tuberculosis and S. aureus. Mr. Naidich is a seasoned entrepreneur and accomplished computer scientist

The eGenomics System has been used in beta trials by New York Hospital Queens, a 450 bed teaching hospital in the Cornell University Hospital network. The system is also currently being used to track infectious agents collected from approximately 30 New Jersey hospitals. Scientists at the CDC, Rockefeller University, Duke University Medical Center, Purdue University, The Institute for Genomic Research (TIGR), and other research facilities located in Australia, Japan, Canada, India, Portugal, The Netherlands, Germany, Mexico, Egypt and Scotland currently use the eGenomics Internet database software.